A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
A phase 1/2 trial of Durvalumab, Capivasertib, Oleclumab, Trastuzumab deruxtecan and Datopotamab deruxtecan in triple-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer is a phase 1/2 interventional study registered as NCT03742102 by AstraZeneca, with 243 participants enrolled, started 2018-12-21 and due to reach its primary completion in 2024-11-29. Interventions recorded: Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan and Datopotamab deruxtecan. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialCapivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Shares Capivasertib, AstraZeneca, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
Shares Datopotamab deruxtecan, AstraZeneca, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialOleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
Shares Oleclumab, AstraZeneca and the tag pipeline.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Datopotamab deruxtecan, Durvalumab, AstraZeneca and the tag pipeline.
- TrialStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Shares Datopotamab deruxtecan, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Durvalumab, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialA Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Shares Durvalumab, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Shares Capivasertib, AstraZeneca and the tag pipeline.